Top Markets
#1 Nesa Nesa +805.02%
#2 Cortex Cortex +68.45%
#3 Merlin's Seal BTC Merlin's Seal BTC +45.39%
#4 QuantixAI QuantixAI +24.45%
#5 Pons Pons +24.38%
#6 EXOD EXOD +22.78%
#7 Instadapp Instadapp +21.54%
#8 Movement Movement +12.08%
#9 SkyAI SkyAI +11.94%
#10 PondCoin PondCoin +10.92%
Coin of the day
Nesa Nesa
Settings
Language
ENGLISH
Currency
USD
Theme
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd

688336
Rank in Stocks #3341
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a... Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a biopharmaceutical enterprise operating in China. This company is thoroughly engaged in the full lifecycle of antibody-based medicines, from their initial research and development to their production and subsequent market introduction. Its current portfolio includes YISAIPU, a tumor necrosis factor inhibitor utilized for treating rheumatic ailments; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody delivered via injection; and Cipterbin, an anti-HER2 monoclonal antibody. Furthermore, the organization is actively progressing novel treatments designed for autoimmune disorders, various cancers, and other health issues. Established in 2002, its main offices are situated in Shanghai, China.
Share Price
$6.27
Market Cap
$5.62B
Change (1 day)
-0.46%
Change (1 year)
26.35%
Country
CN
Trade Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)

Category

Healthcare
Revenue for Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Revenue in Aug 2026 TTM: 0
According to Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH